Background: In the general population, the exercise treadmill testing variables of lower resting heart rate, higher peak heart rate, and greater fitness have favorable prognosis for mortality. Patients with obstructive lung disease have increased mortality risk. Furthermore, some pulmonary medications (ie, beta2-agonists) can influence heart rate. We determined whether exercise treadmill test parameters carry the same prognostic value in patients who are using versus not using pulmonary medications.
Methods: We analyzed data on 69,855 patients (mean age, 55 years) who completed a clinically indicated exercise treadmill test. Patients were defined as having "lung disease" if they were taking medications routinely used to treat obstructive lung disease (n = 6145, 9%). International Classification of Diseases, 9th Revision codes regarding the type of lung disease were not available. Multivariate-adjusted Cox models were used to determine the risk of mortality, major adverse cardiac events, and myocardial infarction over a mean of 11 years follow-up.
Results: Higher resting heart rate was associated with increased mortality risk, and higher peak heart rate and fitness were associated with decreased risk. No significant interaction for lung disease status was seen for the heart rate variables, but a slightly stronger protective effect was observed for higher fitness among patients with lung disease (P interaction = .032). The results were similar for major adverse cardiac events and myocardial infarction.
Conclusions: Heart rate parameters achieved on exercise treadmill tests are equally prognostic among patients using versus not using pulmonary medications. Higher fitness was associated with improved clinical outcomes for both; however, the relative benefit of fitness on survival was even greater in patients using pulmonary medications compared with those not using them.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536900 | PMC |
http://dx.doi.org/10.1016/j.amjmed.2015.11.013 | DOI Listing |
Lasers Med Sci
January 2025
Cornell University, Ithaca, USA.
Purpose: Photobiomodulation (PBM) is a non-invasive therapeutic procedure that consists of irradiating a local area of the skin with red and near-infrared lasers or light emitting diodes (LEDs). Local PBM has been studied as a method to improve exercise performance and recovery. This review aims to evaluate the efficacy of whole-body PBM for exercise performance and recovery, comparing its findings to the established effects of localized PBM.
View Article and Find Full Text PDFCurr Rheumatol Rep
January 2025
Division of Rheumatology, Department of Pediatrics, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA.
Purpose: To summarize the latest research on the epidemiology, pathogenesis, diagnosis, and treatment of multisystem inflammatory syndrome in children (MIS-C).
Recent Findings: The epidemiology of MIS-C has been dynamic since its initial description. The pathogenesis remains poorly understood.
Eur J Pediatr
January 2025
Service de Physiologie Pédiatrique-Centre du Sommeil-CRMR Hypoventilations Alvéolaires Rares, INSERM NeuroDiderot, Université Paris-Cité, AP-HP, Hôpital Robert Debré, Paris, France.
Unlabelled: It is known that in most cases of congenital central hypoventilation syndrome (CCHS), apnoeas and hypoventilation occur at birth. Nevertheless, a detailed description of initial symptoms, including pregnancy events and diagnostic tests performed, is warranted in infants with neonatal onset of CCHS, that is, in the first month of life. The European Central Hypoventilation Syndrome Consortium created an online patient registry from which 97 infants (44 females) with CCHS of neonatal onset and PHOX2B mutation from 10 countries were selected.
View Article and Find Full Text PDFJ Perinat Neonatal Nurs
January 2025
Author Affiliations: Departments of Midwifery (Mr Fikadu), Internal Medicine (Dr Shibru), and Obstetrics and Gynecology (Drs Koira, Chufamo, and Mulugeta), and School of Public Health (Messrs Kote and Hailemariam and Dr Ayele), College of Medicine and Health Sciences, Arba Minch University, Southern Region, Arba Minch, Ethiopia; Ethiopia Midwives Association, Addis Ababa, Ethiopia (Messrs Belgu and Mazengia); and Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Amhara Region, Gondar, Ethiopia (Dr Ayele).
Purpose: This study was aimed to assess the effect of intermittent fetal heart rate (FHR) monitoring using Moyo Doppler compared with fetoscope in hospitals of Ethiopia, 2023.
Background: To facilitate more prompt identification of a hypoxic fetus, Laerdal Global Health has recently introduced the Moyo FHR monitor. Nevertheless, there exists limited knowledge regarding its efficacy derived from multicenter contextual trials conducted in resource-constrained environments, specifically in Ethiopia.
Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!